DGAP-News: Evotec and Bayer enter into multi-target alliance to fight Endometriosis
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Alliance
Evotec and Bayer enter into multi-target alliance to fight
Endometriosis
01.10.2012 / 10:42
---------------------------------------------------------------------
Hamburg, Germany - 01 October 2012: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX) today announced that Evotec and Bayer Pharma AG have entered
into a five-year, multi-target collaboration with the goal of developing
three clinical candidates for the treatment of endometriosis. Both parties
will contribute innovative drug targets and high quality technology
infrastructures and will share the responsibility for early research and
pre-clinical characterisation of potential clinical candidates in the
disease area of endometriosis.
Bayer will be responsible for any subsequent clinical development and
commercialisation. Evotec will receive EUR 12 million as an upfront
payment. Evotec may also receive additional pre-clinical, clinical and
sales milestones of potentially up to approximately Euro 580 million, plus
potential royalties of up to low double digit percent of net sales,
depending on which party brought the compound to the collaboration and the
successful development and approval of potential drug candidates.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: 'Women
with endometriosis may experience excruciating and chronic pain. Because
endometriosis affects women in childbearing age, there is an incredible
need for new, non-surgical treatments that will preserve fertility and
alleviate pain. Evotec brings into this collaboration potential drug
candidates and its extensive know-how in the area of chronic pain. We look
forward to joining forces with Bayer in what we believe is a very promising
and comprehensive effort to tackle this significant issue in women's
health.'
'Endometriosis is a disease with insufficient treatment options today for
women who suffer from this painful condition. It is one of Bayer's
strategic research indications and our new collaboration with Evotec will
perfectly complement our activities in this field of high unmet medical
need', said Prof Andreas Busch, Member of the Bayer HealthCare Executive
Committee and Head of Global Drug Discovery. 'We look forward to working
with Evotec's team on the development of novel drug candidates.'
About Endometriosis
Endometriosis affects an estimated 176 million women worldwide or 10% of
women of reproductive age. It is caused by the abnormal growth of tissue
similar to that which lines the uterus (endometrial tissue) in locations
outside of the uterine cavity, where it causes ectopic lesion growth and
debilitating pain. Endometrial growth is commonly found on the ovaries and
pelvic peritoneum, potentially involving other organs of the pelvic cavity
as e.g. bladder, bowel, and the rectovaginal space.
There is no known cure for endometriosis and most available drug treatments
have certain limitations. Endometriosis is a highly complex and
heterogeneous disease and there is still a high unmet medical need for
innovative therapies which address the individual needs of affected women.
The disease can greatly impact a woman's social, professional and personal
life, and women with endometriosis often experience a higher incidence of
depression and emotional distress due to the uncertainty of diagnosis,
unpredictability of symptoms and living a normal life.
Find more information at http://endometriosisfoundation.org or
http://endometriosis-league.eu/en.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
01.10.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
187146 01.10.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.10.2012 - 10:42 Uhr
Sprache: Deutsch
News-ID 188027
Anzahl Zeichen: 2617
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec and Bayer enter into multi-target alliance to fight Endometriosis"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
